normal 0 false false false en-us x-none ar-sa background: from the thousands of years, metal compounds have been used in medicine for treatment of various diseases including various types of cancers. ruthenium was seen as a promising metal due to its similar kinetics to platinum and its lower toxicity. therefore, we aimed to evaluate the newer mononuclear ruthenium (ii) compounds for antinocice...

Fully reversible photoswitching of the coordination mode of the ligand MeN4Py (1,1-di(pyridin-2-yl)-N,N'-bis(pyridin-2-yl-methyl)-ethan-1-amine) in its ruthenium(II) complex with visible light is reported. Irradiation with visible light results in dissociation of a pyridyl moiety, which is reversed by irradiation at 355 nm.

Two novel tris(bipyridine)ruthenium(II) complexes bearing two and six beta-cyclodextrin binding sites on their ligands have been synthesised and characterised. Complex 1, bearing two cyclodextrins, adopts a conformation in aqueous solution where parts of the aromatic ligands are self-included into the cyclodextrin moieties. This results in a loss of symmetry of the complex and gives rise to a m...

The regioselective cyclometalation of 4-(pyridin-2-yl)phthalimide was exploited for the economical design of organometallic protein kinase inhibitors. 4-(Pyridin-2-yl)phthalimide can be prepared from inexpensive 4-bromophthalimide in just three steps including one Pd-catalyzed Stille cross-coupling. The versatility of this new ligand was demonstrated with the synthesis of ruthenium(II) half-san...